Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
June 11, 2018AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 11, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), focused on prolonging healthspan through an understanding of the fundamental mechanisms of human aging, today announced that it has closed a $5 million equity financing, through the sale of two million AgeX common shares to Juvenescence Ltd. Following the sale, BioTime owns approximately 80.6% of AgeX’s outstanding ... 
Printer Friendly Version
June 08, 2018BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
- Draft registration statement filed on Form 10 with the U.S. Securities and Exchange Commission - ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 8, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.S. Securities and Exchange Commission (the “SEC”). The draft registration statement relates to the pro... 
Printer Friendly Version
June 05, 2018AgeX Therapeutics Appoints John F. Mauldin to Board of Directors
Bestselling financial writer and visionary joins AgeX Board as Company enters next phase of growth ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 5, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) focused on prolonging healthspan through an understanding of the fundamental mechanisms of human aging, today announced the appointment of financial expert, commentator, and bestselling author John F. Mauldin to its ... 
Printer Friendly Version
May 30, 2018BioTime to Present at the 8th Annual LD Micro Invitational
ALAMEDA, Calif.--(BUSINESS WIRE)--May 30, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the 8th Annual LD Micro Invitational Conference on Monday, June 4, 2018 at 1:30pm PT, at the Luxe Sunset Bel Air Hotel in Los Angeles, California. Mr. Skibsted will also be meeting with investors... 
Printer Friendly Version
May 29, 2018BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
ALAMEDA, Calif.--(BUSINESS WIRE)--May 29, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million... 
Printer Friendly Version
May 24, 2018BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites
Diana V. Do, MD, Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine David Telander, MD, PhD at The Retinal Consultants Medical Group serving northern California ALAMEDA, Calif.--(BUSINESS WIRE)--May 24, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the expansion of its ongoing Phase I/II... 
Printer Friendly Version
May 17, 2018AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
ALAMEDA, Calif.--(BUSINESS WIRE)--May 17, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that the company’s Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will deliver a keynote presentation at World Advanced Therapies & Regenerative Medicine Congress, May 16-18 in London. Taking place on Friday, May 18 at 12:30pm BST, Dr. West’s presenta... 
Printer Friendly Version
May 10, 2018BioTime Reports First Quarter Results and Recent Corporate Accomplishments
Renevia® CE Mark application successfully submitted for European approval OpRegen® cohort 4 initiated in better-vision patients OpRegen® data slides, conference call and webcast today at 1:30pm PT/4:30pm ET ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial re... 
Printer Friendly Version
May 02, 2018AgeX Announces NIH Grant Award
Grant of Approximately $386,000 Will Enable Company to Accelerate its Clinical Development Programs for the Treatment of Diseases of Aging ALAMEDA, Calif.--(BUSINESS WIRE)--May 2, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced the award of a grant of approximately $386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The ... 
Printer Friendly Version
May 01, 2018BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
Signs of structural improvement in the retina Signs of a reduction and change in drusen material Signs of engraftment and cell survival have been maintained for over 2 years in some patients ALAMEDA, Calif.--(BUSINESS WIRE)--May 1, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that an abstract related to one of it... 
Printer Friendly Version
April 26, 2018BioTime to Announce First Quarter 2018 Results on May 10, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 26, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, May 10, 2018, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to disc... 
Printer Friendly Version
April 16, 2018Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
OpRegen® is in a Phase I/IIa clinical trial for dry-AMD Retinal Restoration – Our 3-Dimensional Retinal Tissue Program ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 16, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® clinical trial and Retinal Restoration program will be presented at the upcoming Association for R... 
Printer Friendly Version
April 09, 2018Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 9, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that data from the ongoing OpRegen® trial will be presented at the upcoming Fifth Annual Retinal Cell and Gene Therapy Innovation Summit. The presentation will take place on April 27th, 2018 from 8:15am – 8:30am local time, in Honolulu, Hawaii. The OpRegen® data will be presen... 
Printer Friendly Version
March 27, 2018BioTime Announces Cash Sale of Ascendance Biotechnology
BioTime subsidiary, AgeX, to receive up to $3.5 million in cash ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 27, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that IVT Holdings acquired Ascendance Biotechnology, Inc. BioTime’s subsidiary, AgeX Therapeutics, Inc. (AgeX), owned a minority stake in Ascendance at the time of the acquisition. AgeX will receive up to $3... 
Printer Friendly Version
March 15, 2018BioTime Reports Fourth Quarter and Fiscal 2017 Results
Renevia® CE Mark application submitted for European approval OpRegen® receives DSMB approval to proceed to cohort 4 OpRegen® cohort 4 will include better vision patients and an array of additional functional assessments ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 15, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today reported financial ... 
Printer Friendly Version
March 13, 2018BioTime Submits CE Mark Application for European Approval of Renevia®
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 13, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design dossier application for CE Mark approval to market Renevia® in Europe. BioTime anticipates CE Mark approval in the second half of 2018. “Submission of the CE Mark application establishes an important milestone for BioTime and we a... 
Printer Friendly Version
March 07, 2018BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
Continued safety from cohorts 1, 2 and 3 included in assessment by independent DSMB Cohort 4 will focus on earlier stage dry-AMD patients Additional functional data assessments are included in Cohort 4 ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 7, 2018-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the indep... 
Printer Friendly Version
March 05, 2018BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 5, 2018-- BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2017 financial and operating results on Thursday, March 15, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, Mar... 
Printer Friendly Version
March 01, 2018AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 1, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX) today announced that the company’s Chief Executive Officer Michael D. West, Ph.D. will participate at three upcoming conferences: the Mauldin Economics Strategic Investment Conference, March 6-9 in San Diego; Undoing Aging, March 15-17 in Berlin, Germany; and the 10th World Congress and Expo on Cell & Stem Cell Re... 
Printer Friendly Version
February 28, 2018BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 28, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioTime, will be presenting at the Raymond James 39th Annual Institutional Investor Conference on Wednesday, March 7, 2018 at 10:25am ET, at the J.W. Marriott Grande Lakes Hotel. ... 
Printer Friendly Version
February 26, 2018BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs
20 years of biopharma clinical development and medical affairs experience Prior Clinical lead for Tysabri at Elan Pharmaceuticals Prior Medical lead for Questcor ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 26, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appoin... 
Printer Friendly Version
February 22, 2018BioTime Appoints Cavan Redmond to Its Board of Directors
Former CEO of WebMD, former General Manager of Wyeth Biopharma and Group President of Pfizer 30 Years of Executive Management and Corporate Strategy Experience in Biopharma ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Cavan Redm... 
Printer Friendly Version
February 15, 2018Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
OpRegen® is in a Phase I/IIa clinical trial for dry-AMD Vision Restoration – Our 3-Dimensional Retinal Tissue Program ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 15, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that two abstracts have been accepted and will be presented at the upcoming Association f... 
Printer Friendly Version
February 07, 2018BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer of BioTime, will participate in the BIO CEO and Investor Conference, on February 12th and 13th 2018, at the New York Marriott Marquis. The BIO CEO and Investor Conference is one ... 
Printer Friendly Version
January 29, 2018Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 29, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal trial of Renevia® in Europe will be presented at the International Master Course on Aging Science (IMCAS) conference on February 3, 2018. The Renevia® data will be presented by primar... 
Printer Friendly Version
January 23, 2018BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 23, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be presenting at the Noble Capital Markets 14th Annual Investor Conference on Monday, January 29, 2018 at 4:00pm ET, at the W Hotel Fort Lauderdale. A webcast of ... 
Printer Friendly Version
January 22, 2018BioTime Announces Clinical and Corporate Milestone Targets for 2018
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 22, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and corporate milestone targets. BioTime will continue to focus on the core pillars of its stated strategy of Clinical Progress, Simplification and Unlocking Value for BioTime Shareholders. ... 
Printer Friendly Version
January 18, 2018AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 18, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that AgeX will present in a Plenary session, “Stem Cell Innovations That Will Change the World – Part 2,” at the World Stem Cell Summit (WSCS) on Thursday, January 25, 2018 at the Hyatt Regency Miami. AgeX CEO Michael D. West, Ph.D. will provide an update on AgeX’s core programs in cardiovascular and... 
Printer Friendly Version
January 17, 2018BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate
BioTime expands and strengthens patent estate covering OpRegen® through 2031 Expanded and strengthened patent coverage of pluripotent cell technology ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 17, 2018-- BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the issuance of 41 new patents over th... 
Printer Friendly Version
January 05, 2018AgeX Therapeutics to Present at Biotech Showcase Annual Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 5, 2018-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that it will present at Biotech Showcase, January 8-10, 2018 at the Hilton San Francisco Union Square. Michael D. West, Ph.D., Chief Executive Officer, will present at the conference as follows: Date: Tuesday, January 9 Time: 2:30 PM PST Track: Yosemite-B (Ballroom Level) Venue: Hil... 
Printer Friendly Version
January 02, 2018AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer
- Published in the peer-reviewed journal Oncotarget – - Potential applications in scarless tissue regeneration, cancer, and aging - ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2018-- AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced a newly-published peer-reviewed study that reveals genes implicated in tissue regeneration, cancer, and aging. The study, by scientists at AgeX and ... 
Printer Friendly Version